• Mutation; HGNC; HGNC:7029; MET; Simple; p.His58Leu; Zygosity=Unspecified (PubMed=29435981).
  

PubMed=18804159; DOI=10.1016/j.ygeno.2008.08.002
Jung J.-J., Jeung H.-C., Chung H.C., Lee J.O., Kim T.S., Kim Y.T., Noh S.H., Rha S.Y.
In vitro pharmacogenomic database and chemosensitivity predictive genes in gastric cancer.
Genomics 93:52-61(2009)

PubMed=23175241; DOI=10.1099/vir.0.045237-0
Kim D.N., Seo M.K., Choi H., Kim S.Y., Shin H.J., Yoon A.-R., Tao Q., Rha S.Y., Lee S.K.
Characterization of naturally Epstein-Barr virus-infected gastric carcinoma cell line YCCEL1.
J. Gen. Virol. 94:497-506(2013)

PubMed=25787276; DOI=10.1128/JVI.03614-14; PMCID=PMC4442510
Palser A.L., Grayson N.E., White R.E., Corton C., Correia S., Ba Abdullah M.M., Watson S.J., Cotten M., Arrand J.R., Murray P.G., Allday M.J., Rickinson A.B., Young L.S., Farrell P.J., Kellam P.
Genome diversity of Epstein-Barr virus from multiple tumor types and normal infection.
J. Virol. 89:5222-5237(2015)

DOI=10.1158/1538-7445.AM2016-139
Kim T.S., Park K.H., Kwon W.S., Lee W.S., Jeong I., Kang S.K., Kim H.M., Rha S.Y., Chung H.C.
Novel gastric cancer cell lines established from diffuse type gastric cancer patients for potential subgroup-specific therapy.
Cancer Res. 76 Suppl. 14:139-139(2016)

PubMed=26889033; DOI=10.1128/JVI.00060-16; PMCID=PMC4836357
Kanda T., Furuse Y., Oshitani H., Kiyono T.
Highly efficient CRISPR/Cas9-mediated cloning and functional characterization of gastric cancer-derived Epstein-Barr virus strains.
J. Virol. 90:4383-4393(2016)

PubMed=29435981; DOI=10.1002/ijc.31304
Kim H.J., Kang S.K., Kwon W.S., Kim T.S., Jeong I., Jeung H.-C., Kragh M., Horak I.D., Chung H.C., Rha S.Y.
Forty-nine gastric cancer cell lines with integrative genomic profiling for development of c-MET inhibitor.
Int. J. Cancer 143:151-159(2018)